Bronchiolitis primary prevention: Difference between revisions
Jump to navigation
Jump to search
m (Bot: Removing from Primary care) |
|||
| (17 intermediate revisions by 8 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Bronchiolitis}} | {{Bronchiolitis}} | ||
{{CMG}}; {{AE}} {{Alonso}} | |||
==Overview== | ==Overview== | ||
Effective measures for the [[primary prevention]] of bronchiolitis include washing hands, avoiding contact with patients with [[symptomatic]] [[respiratory infections]], and [[Prevention (medical)|prevention]] from [[tobacco]] smoke exposure. These [[Preventive medicine|preventive]] measures are aimed at avoiding [[viral]] [[Disseminated disease|dissemination]] during the [[RSV]] season. In patients with a high risk of developing severe [[infection]], [[Immunization#Passive immunization|passive immunization]] with [[Palivizumab|palivizumab]] is recommended. | |||
==Primary Prevention== | |||
===General measures=== | |||
The steps that are taken in order to prevent the spread of the infective bronchiolitis include: | |||
*Covering [[coughs]] and [[sneezes]] with a tissue or upper shirt sleeve, not your hands. | |||
*Washing [[hands]] often with soap and [[water]] for 20 seconds. | |||
*Avoid close contact such as, kissing, shaking hands, and sharing cups or eating utensils. | |||
*Cleaning [[Contamination|contaminated]] surfaces (such as doorknobs) may help stop the spread of [[RSV]]. | |||
Parents of children at high risk for developing severe [[RSV]] disease should help their child by taking the following measures:<ref name="Respiratory Syncytial Virus Infection (RSV)">CDC https://www.cdc.gov/rsv/about/prevention.html Accessed on June 1, 2017 </ref> | |||
*Avoid close contact with sick people. | |||
*Wash the child's hands often with soap and water. | |||
*Avoid touching the child's [[face]] with unwashed hands. | |||
*Limit the time they spend in child-care centers or other potentially [[contagious]] settings, especially during fall, winter, and spring. This may help [[Prevention (medical)|prevent]] [[infection]] and spread of the [[virus]] during [[RSV]] season. | |||
==Palivizumab prophylaxis== | ===Palivizumab prophylaxis=== | ||
Recommendations are based on the 2009 AAP Modified | Recommendations are based on the 2009 AAP Modified Recommendations for use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections.<ref name="pmid19736258">{{cite journal| author=Committee on Infectious Diseases| title=From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. | journal=Pediatrics | year= 2009 | volume= 124 | issue= 6 | pages= 1694-701 | pmid=19736258 | doi=10.1542/peds.2009-2345 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19736258 }} </ref> | ||
*[[Prophylaxis]] is recommended in selected patients with high risk of severe bronchiolitis: | *[[Prophylaxis]] is recommended in selected patients with a '''high risk of severe bronchiolitis''': | ||
:*Patients younger than 2 years of age who | :*Patients younger than 2 years of age who require medical therapy for [[Chronic obstructive pulmonary disease|chronic lung disease]] 6 months or less before the [[RSV]] season. | ||
:*Patients younger than 2 years of age | :*Patients younger than 2 years of age with [[congenital heart disease]]. | ||
::*Infants who are receiving [[congestive heart failure]] treatment. | ::*Infants who are receiving [[congestive heart failure]] treatment. | ||
::*[[ | ::*Infants with [[cyanotic heart disease]]. | ||
::* | ::*Infants with moderate to severe [[pulmonary hypertension]]. | ||
:* | :*'''History of [[prematurity]]''': | ||
::*[[Prophylaxis]] is recommended | ::*[[Prophylaxis]] is recommended for [[premature infants]] with less than 32 weeks of [[gestation]] with or without [[COPD|chronic lung disease]] of prematurity. | ||
::*For patients born with 28 weeks of [[gestation]] or less, [[prophylaxis]] is recommended for their first [[RSV]] season | ::*For patients born with 28 weeks of [[gestation]] or less, [[prophylaxis]] is recommended for their first [[RSV]] season, regardless of the age of the patient. If [[prophylaxis]] is started, it should continue throughout the [[RSV]] season. | ||
::*For patients born with 29 to 32 weeks of [[gestation]], [[prophylaxis]] is recommended for patients are born 6 months or less before the [[RSV]] season. If | ::*For patients born with 29 to 32 weeks of [[gestation]], [[prophylaxis]] is recommended for patients are born 6 months or less before the [[RSV]] season. If [[prophylaxis]] is started, it should continue throughout the [[RSV]] season. | ||
::*For patients | ::*For patients born with 32 to 35 weeks of [[gestation]], [[prophylaxis]] is recommended in patients who are born 3 months before the [[RSV]] season or during the [[RSV]] season and who have 1 of the following risk factors which may require hospitalization due to bronchiolitis: | ||
:::*Infants with school-aged | :::*[[Infants]] with school-aged siblings. | ||
:::*Infants who attend to child care centers. | :::*[[Infants]] who attend to child care centers. | ||
*Infants who have either congenital abnormalities of the airway or [[neuromuscular disease]] that compromises handling of respiratory secretions. | *Infants should not be exposed to [[tobacco]] as it has been shown that it increases the risk of [[RSV]] infection. | ||
*[[Breastfeeding]] lowers the risk of [[Lower respiratory tract infection|lower respiratory tract infections]] in [[infants]] because of ingestion of [[Immune Globulin Intravenous|immune factors]] such as [[Immunoglobulin A|immunoglobulins A]] and [[Immunoglobulin G|G]]. | |||
*The use of alcohol-based rubs or [[antimicrobial]] soaps to maintain correct hand [[hygiene]] in health care workers is important to [[Prevention (medical)|prevent]] [[nosocomial]] dissemination of the [[disease]] when dealing with hospitalized patients | |||
*[[Infants]] who have either [[congenital abnormalities]] of the [[airway]] or [[neuromuscular disease]] that compromises handling of [[respiratory]] [[secretions]]. | |||
====Dosage==== | ====Dosage==== | ||
*15 mg/kg monthly doses to a maximum of 5 doses is the recommended regimen for patients born before 32 weeks of gestation, [[congenital heart disease]] with significant hemodynamic consequences or chronic lung disease. | *15 mg/kg monthly doses to a maximum of 5 doses is the recommended regimen for patients born before 32 weeks of gestation, [[congenital heart disease]] with significant [[Hemodynamics|hemodynamic]] consequences, or [[Lung disease|chronic lung disease]]. | ||
*15 mg/kg | *15 mg/kg monthly doses to a maximum of 3 doses is the recommended regimen for patients born between 32 and 35 weeks of [[gestation]] who meet the criteria for [[prophylaxis]]. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | {{WikiDoc Help Menu}} | ||
[[Category: | {{WikiDoc Sources}} | ||
[[Category: | |||
[[Category:Disease]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Pulmonology]] | |||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Infectious disease]] | |||
Latest revision as of 20:44, 29 July 2020
|
Bronchiolitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Bronchiolitis primary prevention On the Web |
|
American Roentgen Ray Society Images of Bronchiolitis primary prevention |
|
Risk calculators and risk factors for Bronchiolitis primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alonso Alvarado, M.D. [2]
Overview
Effective measures for the primary prevention of bronchiolitis include washing hands, avoiding contact with patients with symptomatic respiratory infections, and prevention from tobacco smoke exposure. These preventive measures are aimed at avoiding viral dissemination during the RSV season. In patients with a high risk of developing severe infection, passive immunization with palivizumab is recommended.
Primary Prevention
General measures
The steps that are taken in order to prevent the spread of the infective bronchiolitis include:
- Covering coughs and sneezes with a tissue or upper shirt sleeve, not your hands.
- Washing hands often with soap and water for 20 seconds.
- Avoid close contact such as, kissing, shaking hands, and sharing cups or eating utensils.
- Cleaning contaminated surfaces (such as doorknobs) may help stop the spread of RSV.
Parents of children at high risk for developing severe RSV disease should help their child by taking the following measures:[1]
- Avoid close contact with sick people.
- Wash the child's hands often with soap and water.
- Avoid touching the child's face with unwashed hands.
- Limit the time they spend in child-care centers or other potentially contagious settings, especially during fall, winter, and spring. This may help prevent infection and spread of the virus during RSV season.
Palivizumab prophylaxis
Recommendations are based on the 2009 AAP Modified Recommendations for use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections.[2]
- Prophylaxis is recommended in selected patients with a high risk of severe bronchiolitis:
- Patients younger than 2 years of age who require medical therapy for chronic lung disease 6 months or less before the RSV season.
- Patients younger than 2 years of age with congenital heart disease.
- Infants who are receiving congestive heart failure treatment.
- Infants with cyanotic heart disease.
- Infants with moderate to severe pulmonary hypertension.
- History of prematurity:
- Prophylaxis is recommended for premature infants with less than 32 weeks of gestation with or without chronic lung disease of prematurity.
- For patients born with 28 weeks of gestation or less, prophylaxis is recommended for their first RSV season, regardless of the age of the patient. If prophylaxis is started, it should continue throughout the RSV season.
- For patients born with 29 to 32 weeks of gestation, prophylaxis is recommended for patients are born 6 months or less before the RSV season. If prophylaxis is started, it should continue throughout the RSV season.
- For patients born with 32 to 35 weeks of gestation, prophylaxis is recommended in patients who are born 3 months before the RSV season or during the RSV season and who have 1 of the following risk factors which may require hospitalization due to bronchiolitis:
- Infants should not be exposed to tobacco as it has been shown that it increases the risk of RSV infection.
- Breastfeeding lowers the risk of lower respiratory tract infections in infants because of ingestion of immune factors such as immunoglobulins A and G.
- The use of alcohol-based rubs or antimicrobial soaps to maintain correct hand hygiene in health care workers is important to prevent nosocomial dissemination of the disease when dealing with hospitalized patients
- Infants who have either congenital abnormalities of the airway or neuromuscular disease that compromises handling of respiratory secretions.
Dosage
- 15 mg/kg monthly doses to a maximum of 5 doses is the recommended regimen for patients born before 32 weeks of gestation, congenital heart disease with significant hemodynamic consequences, or chronic lung disease.
- 15 mg/kg monthly doses to a maximum of 3 doses is the recommended regimen for patients born between 32 and 35 weeks of gestation who meet the criteria for prophylaxis.
References
- ↑ CDC https://www.cdc.gov/rsv/about/prevention.html Accessed on June 1, 2017
- ↑ Committee on Infectious Diseases (2009). "From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections". Pediatrics. 124 (6): 1694–701. doi:10.1542/peds.2009-2345. PMID 19736258.